Milady Mortimer-Oragwu, APRN
Family · Humble, TXNPI 1184863797
Payments from drug & device makers
Across 55 payments — averaging $59.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Photonicare Inc$2K
- Exeltis, USA Inc.$173
- Abiomed$144
- AstraZeneca$137
- Currax Pharmaceuticals LLC$98
- GSK$92
- plus $572 from 16 others
What the payments were for
- Food & beverage$1,19036%
- Education$251%
- Other$2,08363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Photonicare Inc | 1 | $2,083 |
| Exeltis, USA Inc. | 6 | $173 |
| Abiomed | 2 | $144 |
| AstraZeneca | 2 | $137 |
| Currax Pharmaceuticals LLC | 6 | $98 |
| GSK | 6 | $92 |
| Lilly USA, LLC | 4 | $71 |
| Dexcom, Inc. | 3 | $64 |
| Abbott | 3 | $55 |
| Exact Sciences | 3 | $55 |
| Novo Nordisk | 2 | $46 |
| Novartis | 2 | $41 |
| Evoke Pharma, Inc. | 2 | $39 |
| Hologic Sales And Service, LLC | 1 | $28 |
| Genentech USA, Inc. | 4 | $28 |
| Pfizer | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Scynexis, Inc. | 1 | $25 |
| Amgen | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OtoSight Middle Ear Scope$2,083
- BREZTRI$117
How this compares
$3,299 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 19 | $23,099 |
| Nifedipine ErNifedipine | 11 | $924 |
| Gabapentin | 58 | $511 |
| Levothyroxine Sodium | 48 | $493 |
| Hydralazine Hcl | 23 | $411 |
| Atorvastatin Calcium | 71 | $406 |
| Losartan Potassium | 59 | $262 |
| Amlodipine Besylate | 64 | $252 |
| Methocarbamol | 21 | $233 |
| Metoprolol Succinate | 37 | $211 |
| Alendronate Sodium | 15 | $177 |
| Fluticasone Propionate | 12 | $166 |
| Potassium Chloride | 20 | $143 |
| Omeprazole | 25 | $132 |
| Lisinopril | 25 | $121 |
Paid to pharmacies, not to this prescriber.
Other family in Humble
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.